BioCryst Pharmaceuticals BCRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $156.41M+7.5% | $406.56M+209% | $159.4M+36.1% | $163.35M+49.4% | $145.53M+56.9% | ||
| $5.38M+17.7% | $9.52M+56.3% | $2.19M-31.9% | $2.8M+64.7% | $4.57M+261% | ||
| $151.04M+7.1% | $397.03M+217% | $157.21M+38.1% | $160.56M+49.2% | $140.97M+54.1% | ||
| 96.6%-0.3pp | 97.7%+2.3pp | 98.6%+1.4pp | 98.3%-0.2pp | 96.9%-1.8pp | ||
| $60.32M+61.8% | $40.87M-17.3% | $44.6M+8.6% | $43.39M+15.3% | $37.27M-19.8% | ||
| $94.55M+14.7% | $95.78M+19.0% | $83.01M+27.5% | $87.38M+42.7% | $82.47M+38.6% | ||
| $858.01M+590% | $146.17M+7.4% | $129.8M+18.7% | $133.57M+32.8% | $124.31M+15.9% | ||
| -$701.6M-3,405% | $260.39M+5,876% | $29.59M+285% | $29.79M+240% | $21.23M+247% | ||
| -448.6%-463pp | 64%+67.5pp | 18.6%+12.0pp | 18.2%+10.2pp | 14.6%+30.2pp | ||
| $19.78M-15.8% | $14.14M-42.2% | $19.66M-20.8% | $21.58M-12.7% | $23.49M-4.1% | ||
| -$19.21M+6.2% | -$12.37M+42.4% | -$17.46M+17.4% | -$23.3M-9.6% | -$20.47M+0.3% | ||
| -$720.81M-95,193% | $248.02M+1,054% | $12.13M+190% | $6.49M+152% | $758K+102% | ||
| $1M+38.3% | $2.17M+170% | -$769K-231% | $1.4M+715% | $726K+98.9% | ||
| -$721.81M-2,255,763% | $245.85M+1,018% | $12.9M+192% | $5.09M+140% | $32K+100% | ||
| -461.5%-462pp | 60.5%+80.8pp | 8.1%+20.1pp | 3.1%+14.7pp | 0%+38.2pp | ||
| -$2.98— | $1.13+969% | $0.06+186% | $0.02+133% | $0.00+100% | ||
| -$700.54M-3,350% | $260.78M+6,311% | $29.93M+274% | $30.12M+232% | $21.56M+252% | ||
| -447.9%-463pp | 64.1%+67.3pp | 18.8%+11.9pp | 18.4%+10.1pp | 14.8%+30.1pp | ||
| -$701.6M-3,405% | $260.39M+5,876% | $29.59M+285% | $29.79M+240% | $21.23M+247% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioCryst Pharmaceuticals's revenue?
- BioCryst Pharmaceuticals (BCRX) generated $885.7M in revenue over the trailing twelve months, up 75.9% year over year.
- Is BioCryst Pharmaceuticals profitable?
- BioCryst Pharmaceuticals is not currently profitable: it reported a net loss of $458.0M over the trailing twelve months, a -51.7% net margin.
- What are BioCryst Pharmaceuticals's profit margins?
- Gross margin is 97.8% and operating margin is -43.1%, with a -51.7% net margin.
- What is BioCryst Pharmaceuticals's earnings per share?
- BioCryst Pharmaceuticals's diluted EPS over the trailing twelve months is $-1.77.
- Where does BioCryst Pharmaceuticals's income statement data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
